InvestorsHub Logo
Followers 32
Posts 1683
Boards Moderated 0
Alias Born 01/11/2014

Re: None

Friday, 05/03/2019 11:13:18 AM

Friday, May 03, 2019 11:13:18 AM

Post# of 3516
Can please somebody explain me how it's possible that a company with a drug quadrupling survival in ph2 at 2 years vs SOC in inoperable GBM, and in ph3 for the same condition is trading at $15M? I have never seen a company in ph3 cancer trial, with good success probability, trading at such huge discount. Is there anything I am missing here?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DFFN News